시간 외 거래: 12.70

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd 주식(URGN)의 최신 뉴스

Urogen Pharma Ltd (URGN)

Urogen Pharma Ltd 주식(URGN)의 최신 뉴스

UroGen Pharma Ltd. (NASDAQ:URGN) Shares Acquired by Point72 Asset Management L.P. - MarketBeat

UroGen Pharma secures $25M loan, eyes FDA drug approval - Investing.com

Great Point Partners LLC Increases Stock Holdings in UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

UroGen Pharma (URGN): Among the Worst Middle East and Africa Stocks to Buy Now - Yahoo Finance

UroGen Pharma (URGN): Short Seller Sentiment is Bearish On This ADR Stock - Yahoo Finance UK

UroGen Pharma reiterates stock target, outperform on strong FDA prospects By Investing.com - Investing.com Australia

Examining UroGen Pharma Ltd (URGN) more closely is necessary - US Post News

UroGen Pharma Ltd (URGN) gets rating Initiated from Guggenheim - Knox Daily

Closing Bell Recap: UroGen Pharma Ltd (URGN) Ends at 12.84, Reflecting a -2.73 Downturn - The Dwinnex

UroGen Pharma secures US patent for cancer treatment tech - Investing.com

Check Out UroGen Pharma Ltd (URGN)’s Trade Data Rather Than the Analysts’ Views - SETE News

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 - StockTitan

UroGen Receives New U.S. Patent Allowance for Next-Generation Mitomycin-Based Products Expected to Provide Protection Until December 2041 - Yahoo Finance

Certain Ordinary Shares of UroGen Pharma Ltd. are subject to a Lock-Up Agreement Ending on 15-SEP-2024. - Marketscreener.com

UroGen Pharma director resigns, no disagreement cited By Investing.com - Investing.com Australia

UroGen Pharma director resigns, no disagreement cited By Investing.com - Investing.com Canada

UroGen Pharma Ltd [URGN] Records 200-Day SMA of $15.14 - Knox Daily

UroGen Pharma director resigns, no disagreement cited By Investing.com - Investing.com South Africa

UroGen Pharma director resigns, no disagreement cited - Investing.com

UroGen Pharma director resigns, no disagreement cited By Investing.com - Investing.com UK

Market Recap Check: UroGen Pharma Ltd (URGN)’s Negative Finish at 13.05, Up/Down -5.50 - The Dwinnex

URGN’s Stock Market Pendulum: Swinging Between Gains and Losses - The InvestChronicle

UroGen Pharma CMO sells shares worth over $11,000 - Investing.com

UroGen Pharma Ltd. (NASDAQ:URGN) Insider Mark Schoenberg Sells 859 Shares - MarketBeat

UroGen Pharma general counsel sells shares worth nearly $20k By Investing.com - Investing.com Canada

UroGen Pharma general counsel sells shares worth nearly $20k By Investing.com - Investing.com Australia

UroGen Pharma CMO sells shares worth over $11,000 By Investing.com - Investing.com UK

UroGen Pharma general counsel sells shares worth nearly $20k By Investing.com - Investing.com UK

Where are the Opportunities in (URGN) - Stock Traders Daily

Cowen AND Company LLC Purchases 472,893 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - MarketBeat

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - StockTitan

UroGen Pharma Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - Business Wire

It makes sense and dollars to buy UroGen Pharma Ltd (URGN) stock - SETE News

UroGen Pharma's JELMYTO And UGN-102: A Strong Buy In The Urological Cancer Sector - Seeking Alpha

UroGen Pharma to Present at Upcoming Investor Conferences - The Bakersfield Californian

UroGen Pharma to Present at Upcoming Investor Conferences - Business Wire

UroGen Pharma: There Is Some Potential Here (NASDAQ:URGN) - Seeking Alpha

The Attractiveness of Investing In UroGen Pharma Ltd (URGN) is Growing - Knox Daily

Holdings of UroGen Pharma Ltd (URGN) are aligned with the stars - SETE News

URGN Shares Experience Decline in Value - Knox Daily

UroGen Pharma (NASDAQ:URGN) Now Covered by Guggenheim - MarketBeat

Ratio Review: Analyzing UroGen Pharma Ltd (URGN)’s Price-to-Cash and Price-to-Free Cash Flow - The Dwinnex

Are UroGen Pharma Ltd’shares a good deal? - US Post News

California State Teachers Retirement System Lowers Position in UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

Vanguard Group Inc. Buys 24,367 Shares of UroGen Pharma Ltd. (NASDAQ:URGN) - Defense World

UroGen Pharma (FRA:UR8) Forward Dividend Yield % : 0.00% (As of Aug. 17, 2024) - GuruFocus.com

UroGen Pharma (FRA:UR8) Revenue : €78.69 Mil (TTM As of Jun. 2024) - GuruFocus.com

URGN (UroGen Pharma) Revenue : $85.01 Mil (TTM As of Jun. 2024) - GuruFocus.com

URGN (UroGen Pharma) EPS (Basic) : $-3.22 (TTM As of Jun. 2024) - GuruFocus.com

URGN (UroGen Pharma) Inventory-to-Revenue : 0.34 (As of Jun. 2024) - GuruFocus.com

HC Wainwright Weighs in on UroGen Pharma Ltd.'s Q3 2024 Earnings (NASDAQ:URGN) - MarketBeat

UroGen Pharma stock maintains steady target with Buy tag from H.C. Wainwright - Investing.com India

UroGen Pharma stock maintains steady target with Buy tag from H.C. Wainwright - Investing.com Australia

Q3 2024 EPS Estimates for UroGen Pharma Ltd. Lowered by HC Wainwright (NASDAQ:URGN) - Defense World

UroGen Pharma Ltd. (NASDAQ:URGN) Released Earnings Last Week And Analysts Lifted Their Price Target To US$43.88 - Yahoo Finance

HC Wainwright Reiterates Buy Rating for UroGen Pharma (NASDAQ:URGN) - Defense World

URGN (UroGen Pharma) Dividend Yield % : 0.00% (As of Aug. 16, 2024) - GuruFocus.com

UroGen Pharma completes FDA submission for cancer drug By Investing.com - Investing.com Canada

UroGen Pharma completes FDA submission for cancer drug - Investing.com

UroGen Pharma completes FDA submission for cancer drug By Investing.com - Investing.com UK

UroGen Pharma completes NDA submission for UGN-102 By Investing.com - Investing.com Australia

UroGen Pharma Ltd (URGN) stock analysis: A comprehensive overview - US Post News

UroGen Pharma (STU:UR8) Future 3-5Y EPS without NRI Growth Rate : 28.37 (As of Aug. 14, 2024) - GuruFocus.com

UroGen Pharma holds neutral rating with $22 price target By Investing.com - Investing.com Australia

UroGen Pharma completes NDA submission for UGN-102 By Investing.com - Investing.com Canada

Financial Health Report: UroGen Pharma Ltd (URGN)’s Ratios Tell a Tale - The Dwinnex

URGN과 유사한 종목